Diabetes, Heart and Cardiovascular Diseases News Chronicle. Diabetes, Cardiovascular and Heart Diseases. Article 115
Published on January 20, 2017 at 10:30 AM


 



New Biomarkers To Predict Diabetes

Previous studies show a direct association between development of type 2 diabetes and worsening of brain health. Now, researchers from Iowa State University discovered new biomarkers to predict type 2 diabetes (T2D) and Alzheimer's disease. Researchers found that autotaxin (an enzyme in the brain) is very effective in predicting type 2 diabetes and Alzheimer's disease.

Researchers analyzed data such as autotaxin levels, memory levels and diabetes in 287 individuals aged 56 to 89 years. In case of a relationship between memory and autotaxin levels, one point increase in autotaxin levels translates into memory decrease of 3.5 to 5 percent. In case of a relationship between diabetes and autotaxin levels, one point increase in autotaxin levels translates into 300 percent increase in development of pre-diabetes or diabetes.

Researchers say autotaxin is a better biomarker in predicting Alzheimer's disease compared with other biomarkers. Researchers say as triglyceride levels increases, autotaxin levels also increase in an individual. Researchers are hoping that patients can get treatment and prevent worse Alzheimer's and diabetes disease situation with the early autotaxin biomarker indicator.

The study was done by Assistant Prof Auriel Willette and by Kelsey McLimans, a graduate research assistant. The study findings were published in the Journal of Alzheimer's Disease.



       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and paste the code below):

Also related to this story
1. Biomarkers To Childhood Obesity
2. Study To Predict Diabetic Nephropathy Disease
3. Device To Predict Diabetes
4. Wearable Technology For Elder Care

 



FDA Approves Novo Nordisk Drug Xultophy

Xultophy drug made by Novo Nordisk has been approved by United States FDA based on the results of DUAL and subsequent clinical trials. Few facts about this drug are

  • This is a basal insulin drug and glucagon-like peptide-1 (GLP-1) receptor agonist. This drug is intended to improve glycemic control in type 2 diabetes patients
  • This drug combines one unit of insulin degludec (Tresiba) and 0.036 mg liraglutide (Victoza)
  • This drug works along with diet, physical activity & exercise to type 2 diabetes adult patients whose sugar levels were not controlled with less than 50 units of daily basal insulin or less than 1.8 mg of daily liraglutide medication
  • This drug can be taken with or without food. Once in a day injection dosage in the form of a pre-filled pen

The drug is expected in the United States market during the first half of 2017. Dr. John Buse from the University of North Carolina School of Medicine, Chapel Hill was the principal investigator of DUAL II trial.



       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and paste the code below):

Also related to this story
1. FDA Approval Of Jardiance Drug
2. FDA Clears Xultophy And Soliqua
3. Hypoglycemia & HbA1c. Approval Of Diabetes Drug Xultophy Liraglutide From Novo Nordisk
4. About Long Rapid Short-Intermediate Insulin From Novo Nordisk

 



New Drugs To Fight Heart Complication Due To Diabetes

A study done by scientists from Federal University of Rio de Janeiro (UFRJ) shows a way to prevent heart arrhythmias disease due to high blood sugar levels. Scientists say high blood sugar levels cause inflammation and inflammation cause the production of IL-1-beta (also known as leukocytic pyrogen). IL-1-beta leads to arrhythmias condition in the heart.

Scientists say there are two drugs which can block the production of IL-1-beta and prevent heart changes. They are

  • MCC-950
  • Anakinra

Experiments with mice models were successful. Prof Medai says the study results are very encouraging to treat heart disease caused due to diabetes. This study was coordinated by Prof Emiliano Medei and the study findings were published in the Nature Communications.



       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and paste the code below):

Also related to this story
1. Complication With Belly Fat
2. Complication With Invokana
3. About Meizus H1 Wearable Device
4. Wearable Devices Market

 



Reducing Risks To Cardiovascular Disease

A study done by researchers shows lifetime risk with cardiovascular disease can be reduced by 90 percent with the combination of lower levels of LDL cholesterol and lower levels of systolic blood pressure. Risks with LDL cholesterol and systolic blood pressure to cardiovascular disease are independent, multiplicative and cumulative. Researchers studied cardiovascular risks associated with genetic risk factors of 102,773 individuals with the outcome of diseases such as

Dr. Brian Ference says the cardiovascular disease can be preventable if an individual achieves lower LDL levels and lower systolic blood pressure. Researchers need to focus on studies to find who gets most of the benefits with an early intervention. Lifestyle changes can improve cholesterol and blood pressure levels in an individual and helps in reducing cardiovascular diseases. Lead investigator of the study is Dr. Brian Ference.



       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and paste the code below):

Also related to this story
1. Type 2 Diabetes Risks With Iron Levels
2. Decrease Risks With Sauna Bathing
3. Cardiovascular Risk In Pregnant Women With Gestational Diabetes
4. Small Risk Of Cardiovascular Diseases & Diabetes With Butter Consumption

 



Categories

Sitemap 1   Sitemap 2   Sitemap 3   Sitemap 4

 

The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.


Published by Jammi Vasista, Chennai, India.
Email Jammi[no-space]Vasista1991[at]gmail[dot]com
Phone 91-944-578-3182.
Address Diabetes News Chronicle, No 40, Kaveri Street, Rajaji Nagar, Villivakkam, Chennai, India. Pin : 600049.